Seeing Is Believing
Currently out of the existing stock ratings of Dennis Ding, 9 are a BUY (75%), 3 are a HOLD (25%).
Analyst Dennis Ding, currently employed at JEFFERIES, carries an average stock price target met ratio of 41.67% that have a potential upside of 20.61% achieved within 100 days.
Dennis Ding’s has documented 24 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 27-Sep-2023.
Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) at 10/17/2022. The price target of $4 was fulfilled within 3 days with a profit of $0.59 (17.3%) receiving and performance score of 57.67.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$5
$1.36 (37.36%)
$5
16 days ago
(07-Nov-2024)
0/15 (0%)
$1.27 (34.05%)
Buy
$5
$1.36 (37.36%)
$4
3 months 21 days ago
(02-Aug-2024)
2/6 (33.33%)
$1.26 (33.69%)
256
Buy
$4
$0.36 (9.89%)
$4
5 months 18 days ago
(05-Jun-2024)
4/10 (40%)
$0.37 (10.19%)
136
Buy
$5
$2.08 (71.23%)
2 years 9 months 21 days ago
(02-Feb-2022)
0/1 (0%)
$2.11 (73.01%)
Buy
$7
3 years 4 months 26 days ago
(28-Jun-2021)
0/4 (0%)
$3.7 (112.12%)
What Year was the first public recommendation made by Dennis Ding?